General Information of Drug Therapeutic Target (DTT) (ID: TT4NXYM)

DTT Name Human immunodeficiency virus Negative factor (HIV nef)
Synonyms nef; Nef protein; F-protein; 3'ORF; 27 kDa protein
Gene Name HIV nef
DTT Type
Clinical trial target
[1]
BioChemical Class
Lentivirus primate group Nef
UniProt ID
NEF_HV1A2
TTD ID
T83793
Sequence
MGGKWSKRSMGGWSAIRERMRRAEPRAEPAADGVGAVSRDLEKHGAITSSNTAATNADCA
WLEAQEEEEVGFPVRPQVPLRPMTYKAALDISHFLKEKGGLEGLIWSQRRQEILDLWIYH
TQGYFPDWQNYTPGPGIRYPLTFGWCFKLVPVEPEKVEEANEGENNSLLHPMSLHGMEDA
EKEVLVWRFDSKLAFHHMARELHPEYYKDC
Function Extracellular Nef protein targets CD4(+) T-lymphocytes for apoptosis by interacting with CXCR4 surface receptors.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
4 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
F4co vaccine DM6UQNW Human immunodeficiency virus infection 1C62 Phase 2 [1]
LIPO-5 DMWY0V1 Human immunodeficiency virus infection 1C62 Phase 2 [2]
Ad35-GRIN DM4L28K Human immunodeficiency virus infection 1C62 Phase 1/2 [3]
Ad35-GRIN/ENV DMG82ZA Human immunodeficiency virus infection 1C62 Phase 1 [3]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
GSK-732461 DMJ0ZB6 Human immunodeficiency virus infection 1C62 Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
MYRISTIC ACID DMYX0BL Discovery agent N.A. Investigative [5]
------------------------------------------------------------------------------------

References

1 EP patent application no. 2621528, Vaccine.
2 HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
3 A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
4 Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
5 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.